Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 4, 2011

Exelixis to commence prostate cancer drug trial

Exelixis has announced that it will begin the pivotal Phase III '306 trial of cabozantinib in patients with metastatic castration-resistant prostate cancer by the end of 2011.

Exelixis has announced that it will begin the pivotal Phase III ‘306 trial of cabozantinib in patients with metastatic castration-resistant prostate cancer by the end of 2011.

The double-blind ‘306 trial is expected to enrol 246 CRPC patients, who will be randomised 1:1 to receive either cabozantinib or mitoxantrone / prednisone.

The alleviation of bone pain will be the primary endpoint of the study, while secondary endpoints include overall survival rate and bone scan response.

An earlier Phase II trial with cabozantinib demonstrated favourable effects on bone and soft tissue lesions, and in the relief of bone metastasis-related pain in castration-resistant prostate cancer patients.

Related Companies

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU